Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis
Buy NowEpilepsy Drugs Market Outlook
Renub Research forecasts that by 2030, the global epilepsy drugs market is expected to approach approximately US$ 10.28 billion. Epilepsy drugs play a giant function in the healthcare zone worldwide because of the substantial occurrence of epilepsy, impacting a giant quantity of people. The persistent demand for these medicines is driven by the necessity to correctly manipulate and control seizures. Additionally, ongoing advancements in drug improvement and remedy techniques always enlarge the options available to sufferers and healthcare companies. This popularity underscores the essential role of epilepsy drugs in enhancing patient outcomes and enhancing the satisfaction of lifestyles for those affected by epilepsy.
Between 2024 and 2030, the global epilepsy drugs market is predicted to develop at a compound annual growth rate (CAGR) of 4.37%
The World Health Organization (WHO) states that, epilepsy ranks among the most common neurological conditions worldwide, impacting an estimated 50 million individuals. The marketplace is witnessing boom propelled by the advent of recent and stepped forward medicinal drugs, offering additional remedy alternatives. Addressing the evolving wishes of individuals with epilepsy through advanced pharmaceutical interventions will become essential, given the interplay of these factors.
Further, innovative drug formulations like extended-release drugs and novel drug delivery methods are improving the variety of treatment options available for epilepsy patients. These new improvements in drug delivery technology assist in addressing demanding situations like dosing frequency and fluctuating blood levels, ultimately leading to higher patient effects. Matching treatment techniques to precise epilepsy kinds and individual patient necessities increases the need for a wide range of medications, supporting the development of the global epilepsy drugs market. The market strives to satisfy the evolving needs of patients worldwide by providing numerous medicine options to enhance patient compliance and treatment efficacy.
Also, the significant market percentage for epilepsy drugs may be in North America. This is because of a boom in neurological problems like Parkinson's ailment, along with multiplied focus and tremendous research outcomes. The US invests in growing new epilepsy drugs, enhancing the general marketplace. According to the Parkinson's Foundation, 930,000 humans within the US have Parkinson's ailment, and this is anticipated to develop to 1.2 million by 2030. The Asia-Pacific region is also increasing and is estimated to have the fastest expansion because of the large population there. Epilepsy is a significant healthcare challenge in that place because of the wide variety of people affected by it. Hence, the global epilepsy drugs market was valued at US$ 7.62 Billion in 2023.
The epilepsy drugs market has a significant share of the second-generation drug category
By drug category, the global epilepsy drugs market is fragmented into First Generation Drugs, Second Generation Drugs, and Third Generation Drugs. The phase of second-generation medicinal drugs held a sizeable portion of the epilepsy drugs market, largely because of their focused method of addressing various sorts of seizures with decreased side effects. Additionally, they offer broader applicability and a lower danger of drug interactions. Referred to as more modern AEDs (antiepileptic drugs), second-generation medicines constitute an extra modern-day class of antiepileptic treatments developed through researchers to improve efficacy, tolerability, and protection compared to their predecessors. Examples consist of levetiracetam, lamotrigine, and topiramate.
Focal seizures command a prominent share in the global epilepsy drug market
By seizure types, the global epilepsy drugs market is segmented into Focal Seizures, Generalized Seizures, and Non-Epileptic Seizures. Focal seizures are anticipated to be among the most remarkable portions of the global epilepsy drugs market. This is because of their vast occurrence and diverse manifestations. As one of the most common seizure types, focal seizures affect a massive number of epilepsy sufferers across the world. Their numerous presentations, from subtle to severe, necessitate diverse remedy alternatives, pivoting the call for pharmaceutical interventions. Companies prioritize studies and development of drugs tailored to address the particular needs of individuals experiencing focal seizures, solidifying their prominence inside the epilepsy drugs market.
The drug stores and retail pharmacies segment had one of the highest shares in the global epilepsy drugs market
By distribution channels, the global epilepsy drugs market is categorized into hospital pharmacies, drug stores, retail pharmacies, and online providers. The drug stores and retail pharmacies section stands out as having one of the most substantial shares within the international epilepsy tablets market. This is driven by the extensive accessibility of these outlets, imparting convenient access to a wide variety of antiepileptic medicines. Patients frequently rely upon these institutions for routine prescription refills and pharmacist consultations, contributing drastically to the section's market percentage. Drug shops and retail pharmacies' convenience, availability, and information solidify their pivotal function in distributing epilepsy drugs worldwide.
United States has the lion's share of the global epilepsy drugs market
By countries, the global epilepsy drug market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand), Latin America (Brazil, Mexico, Argentina), Middle East & Africa (South Africa, Saudi Arabia, United Arab Emirates), and Rest of the World. The United States is projected to experience a substantial increase in the market for epilepsy drugs. This is because of the increasing burden of epilepsy and the market players' strategic projects, focus campaigns, and the launch of the latest products. According to a press release of the CDC in 2022, around 3.4 million Americans have epilepsy, and about 1 in 10 people may additionally experience a seizure throughout their lifetime. The United States has over 260 epilepsy centers, wherein healthcare vendors concentrate on dealing with epilepsy and offering professional care to kids and adults. As a result, the prevalence of epilepsy within the area is predicted to force the demand for its remedy, leading to an expanded market increase.
Key Players
Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc., Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., GSK plc, Novartis AG., and Pfizer Inc. are the businesses in the global epilepsy drugs market.
- In January 2023 - Zydus Lifesciences established Topiramate extended-release capsules, a generic medication for treating epilepsy in the United States market.
- In March 2022 - Lupin's abbreviated new Vigabatrin application (ANDA), an antiepileptic drug available as an oral solution USP (500 mg), received approval from the United States Food and Drug Administration.
Drug Category – Market breakup in 4 viewpoints:
1. First Generation Drugs
2. Second Generation Drugs
3. Third Generation Drugs
Seizure Types – Market breakup in 3 viewpoints:
1. Focal Seizures
2. Generalized Seizures
3. Non-Epileptic Seizures
Distribution Channel – Market breakup in 3 viewpoints:
1. Hospital Pharmacies
2. Drug Stores and Retail Pharmacies
3. Online Providers
Countries – Market breakup in 26 viewpoints:
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
6. Rest of the World
All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis
Company Analysis:
1. Eisai Co., Ltd.
2. UCB Inc.
3. H. Lundbeck A/S
4. GW Pharmaceuticals Plc.
5. Abbott Laboratories
6. Alkem Laboratories Limited
7. Bausch Health Companies Inc.
8. GSK plc
9. Novartis AG.
10. Pfizer Inc.
Report Details:
| Report Features | Details |
| Base Year | 2023 |
| Historical Period | 2019 - 2023 |
| Forecast Period | 2024 - 2030 |
| Market | US$ Billion |
| Segment Covered | Drugs Category, Seizure Type, Distribution Channel, and Countries |
| Countries Covered | United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, United Arab Emirates, South Africa, and Rest of the World |
| Companies Covered | Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc., Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., GSK plc, Novartis AG., and Pfizer Inc. |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Exploring the Disease – Background and Key Insights
5.1 Introduction
5.2 Causes
5.3 Classificationof Epilepsies
5.3.1 West Syndrome
5.3.2 Dravet syndrome
5.3.3 Lennox–Gastaut syndrome
5.3.4 Landau–Kleffner syndrome
5.3.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)
5.3.6 CDKL5 deficiency disorder (CDD)
5.4 Risk Factors
5.5 Pathophysiology
5.6 Diagnosis
5.6.1 Diagnostic Guidelines
5.6.1.1 NICE: Epilepsies in Children, Young People, and Adults (2022)
5.6.1.2 American Family Physician: Diagnostic Evaluation (2017)
5.6.1.3 The French National Authority for Health (HAS): 2020
5.6.1.4 German Society for Neurology (DGN) Guidelines: Diagnostics and Therapy in Neurology (2023)
5.7 Treatment
5.7.1 Antiepileptic Medications (AEDs)
5.7.2 Receptor Blockers
5.7.3 Others
5.7.4 Diet Therapy
5.7.5 Surgery
5.7.5.1 Phase I Evaluation (Noninvasive Tests)
5.7.5.2 Phase II Evaluation (Invasive Mon)
5.7.6 Treatment Algorithm for Medical Condition
5.7.7 Treatment Guidelines
5.7.7.1 American Epilepsy Society
5.7.7.2 American Family Physician – Epilepsy Treatment Options (2017)
5.7.7.3 The International League against Epilepsy (ILAE) Epilepsy Guidelines
5.7.7.4 NICE Guidelines: (2022)
5.7.8 Living and Coping with Epilepsy
6. Global Epilepsy Drugs Market
7. Market Share
7.1 By Drugs Category
7.2 By Seizure types
7.3 By Distribution Channels
7.4 By Countries
8. Drugs Category
8.1 First Generation Drugs
8.2 Second Generation Drugs
8.3 Third Generation Drugs
9. Seizure Types
9.1 Focal Seizures
9.2 Generalized Seizures
9.3 Non-Epileptic Seizures
10. Distribution Channels
10.1 Hospital Pharmacies
10.2 Drug Stores and Retail Pharmacies
10.3 Online Providers
11. Countries
11.1 North America
11.1.1 United States
11.1.2 Canada
11.2 Europe
11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Belgium
11.2.7 Netherland
11.2.8 Turkey
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Thailand
11.3.6 Malaysia
11.3.7 Indonesia
11.3.8 Australia
11.3.9 New Zealand
11.4 Latin America
11.4.1 Brazil
11.4.2 Mexico
11.4.3 Argentina
11.5 Middle East & Africa
11.5.1 Saudi Arabia
11.5.2 UAE
11.5.3 South Africa
11.6 Rest of the World
12. Porter’s Five Forces Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Rivalry
12.4 Threat of New Entrants
12.5 Threat of Substitutes
13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat
14. Analysis of Marketed Medications/Drugs
14.1 Key Players
14.2 EPIDIOLEX/EPIDYOLEX (cannabidiol) – Jazz Pharmaceuticals
14.2.1 Description of Drugs
14.2.2 Regulatory Milestones
14.2.3 Clinical Development Process
14.2.4 Safety and Efficacy
14.3 XCOPRI/ONTOZRY(cenobamate) – SK Biopharmaceutical/ Pharma/Ono Pharmaceutical
14.3.1 Description of Drugs
14.3.2 Regulatory Milestones
14.3.3 Clinical Development Process
14.3.4 Safety and Efficacy
14.4 FINTEPLA (fenfluramine) – UCB/Nippon Shinyaku
14.4.1 Description of Drugs
14.4.2 Regulatory Milestones
14.4.3 Clinical Development Process
14.4.4 Safety and Efficacy
14.5 NAYZILAM (midazolam) nasal spray – UCB Pharma
14.5.1 Description of Drugs
14.5.2 Regulatory Milestones
14.5.3 Clinical Development Process
14.5.4 Safety and Efficacy
14.6 VALTOCO (diazepam nasal spray) – Neurelis/Aculys Pharma
14.6.1 Description of Drugs
14.6.2 Regulatory Milestones
14.6.3 Clinical Development Process
14.6.4 Safety and Efficacy
14.7 ZTALMY (ganaxolone) – Marinus Pharmaceuticals/Ovid Therapeutics/Orion
14.7.1 Description of Drugs
14.7.2 Regulatory Milestones
14.7.3 Clinical Development Process
14.7.4 Safety and Efficacy
14.8 BRIVIACT/NUBRIVEO (brivaracetam) – UCB Pharma
14.8.1 Description of Drugs
14.8.2 Regulatory Milestones
14.8.3 Clinical Development Process
14.8.4 Safety and Efficacy
14.9 FYCOMPA (perampanel) – Eisai/Catalyst Pharmaceutical
14.9.1 Description of Drugs
14.9.2 Regulatory Milestones
14.9.3 Clinical Development Process
14.9.4 Safety and Efficacy
14.10 OXTELLAR XR (oxcarbazepine) – Supernus Pharmaceuticals
14.10.1 Description of Drugs
14.10.2 Regulatory Milestones
14.10.3 Clinical Development Process
14.10.4 Safety and Efficacy
14.11 VIMPAT (lacosamide) – UCB Pharma/Daiichi Sankyo
14.11.1 Description of Drugs
14.11.2 Regulatory Milestones
14.11.3 Clinical Development Process
14.11.4 Safety and Efficacy
15. Analysis of Emerging Drugs
15.1 Key Cross Competition
15.2 XEN1101 – Xenon Pharmaceuticals
15.2.1 Description of Drug
15.2.2 Clinical Research & Development
15.2.3 Safety and efficacy
15.3 LIBERVANT (diazepam buccal film) – Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)
15.3.1 Description of Drug
15.3.2 Clinical Research & Development
15.3.3 Safety and efficacy
15.4 Soticlestat (TAK-935) – Takeda/Ovid Therapeutics
15.4.1 Description of Drug
15.4.2 Clinical Research & Development
15.4.3 Safety and efficacy
15.5 COMFYDE (carisbamate) – SK Biopharmaceuticals (SK Life Science)
15.5.1 Description of Drug
15.5.2 Clinical Research & Development
15.5.3 Safety and efficacy
15.6 BHV-7000 (KB-3061) – Biohaven Pharmaceuticals/Knopp Biosciences
15.6.1 Description of Drug
15.6.2 Clinical Research & Development
15.6.3 Safety and efficacy
15.7 STACCATO alprazolam (benzodiazepine) – UCB Pharma/Alexza Pharmaceuticals
15.7.1 Description of Drug
15.7.2 Clinical Research & Development
15.7.3 Safety and efficacy
15.8 NBI-827104 (ACT-709478) – Neurocrine Biosciences/Idorsia Pharmaceuticals
15.8.1 Description of Drug
15.8.2 Clinical Research & Development
15.8.3 Safety and efficacy
15.9 Ivermectin (EQU-001) – Equilibre Biopharmaceuticals
15.9.1 Description of Drug
15.9.2 Clinical Research & Development
15.9.3 Safety and efficacy
16. Regulations and Reimbursement Policies
17. Key Players Analysis
17.1 Eisai Co., Ltd.
17.1.1 Overview
17.1.2 Recent Development
17.1.3 Revenue Analysis
17.2 UCB Inc.
17.2.1 Overview
17.2.2 Recent Development
17.2.3 Revenue Analysis
17.3 H. Lundbeck A/S
17.3.1 Overview
17.3.2 Recent Development
17.3.3 Revenue Analysis
17.4 GW Pharmaceuticals Plc.
17.4.1 Overview
17.4.2 Recent Development
17.4.3 Revenue Analysis
17.5 Abbott Laboratories
17.5.1 Overview
17.5.2 Recent Development
17.5.3 Revenue Analysis
17.6 Alkem Laboratories Limited
17.6.1 Overview
17.6.2 Recent Development
17.6.3 Revenue Analysis
17.7 Bausch Health Companies Inc.
17.7.1 Overview
17.7.2 Recent Development
17.7.3 Revenue Analysis
17.8 GSK plc
17.8.1 Overview
17.8.2 Recent Development
17.8.3 Revenue Analysis
17.9 Novartis AG
17.9.1 Overview
17.9.2 Recent Development
17.9.3 Revenue Analysis
17.10 Pfizer Inc
17.10.1 Overview
17.10.2 Recent Development
17.10.3 Revenue Analysis
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com